Tecentriq
Brand Name: Tecentriq®
Composition: Atezolizumab (1200 mg / 20 mL)
Manufacturer: Roche
Product Description
Medical Info
Tecentriq (Atezolizumab) is an advanced prescription immunotherapy solution formulated for intravenous use after dilution. Operating as a targeted monoclonal antibody, it acts as a programmed death-ligand 1 (PD-L1) blocking agent, helping the patient’s own immune system recognize and combat cancer cells effectively. Supplied as a single vial containing 1200 mg of concentrate per 20 mL of solution, this sterile medication is widely utilized in oncology for treating specific malignancies, including non-small cell lung cancer and urothelial carcinoma. Clinical administration requires strict oncology supervision, precise medical preparation, and personalized dosage management.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
